Search Results 1731-1740 of 14768 for anti-TNF drugs

1. A Study to Evaluate Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Patients - Mayo Clinic

   About this study. The purpose of this study is to evaluate, jointly and independently among patients deemed at higher risk vs. lower risk for disability ...

2. Daratumumab And Hyaluronidase-Fihj (Subcutaneous Route) Description and Brand Names - Mayo Clinic

   Drugs and Supplements · Daratumumab And Hyaluronidase-Fihj (Subcutaneous Route) ... treatment) multiple myeloma in patients who have received at least 1 previous ...

3. Nilotinib (Oral Route) Description and Brand Names - Mayo Clinic

   Nilotinib belongs to the general group of medicines known as antineoplastics or cancer medicines. It interferes with the growth of cancer cells, ...

4. A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis - Mayo Clinic

   Participation eligibility · Any anti-CD20 therapy such as rituximab, ocrelizumab, or ofatumumab less than 9 months prior to screening or during screening; · If an ...

5. Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH) - Mayo Clinic

   antidiabetic drugs, change in anti-diabetic therapy must follow these requirements: no qualitative change 6 months prior to diagnostic liver biopsy up to ...

6. A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Participants With Prostate Cancer - Mayo Clinic

   Drugs & Supplements A-Z · Health Books · Healthy Living Program · Mayo Clinic ... anti-cancer therapy. Biopsy of a progressing metastatic lesion is preferred ...

7. Insulin Human Regular (Intravenous Route, Subcutaneous Route) Description and Brand Names - Mayo Clinic

   Description and Brand Names. Drug information provided by: Merative, Micromedex®. US Brand Name. Myxredlin. Descriptions. Insulin human regular is a ...

8. Beta-2 Adrenergic Agonist (Oral Route, Injection Route) Proper Use - Mayo Clinic

   The following information includes only the average doses of these medicines. If your dose is different, do not change it unless your doctor tells you to do so.

9. Science Saturday: Addressing the challenges of chimeric antigen receptor-T cell therapy - Mayo Clinic News Network

   For example, clinical trials have shown that a single infusion of CAR-T cell therapy targeted against a molecule known as BCMA that marks multiple myeloma cells ...

10. Enfuvirtide (Subcutaneous Route) Proper Use - Mayo Clinic

    Be sure to take all the medicines your doctor has prescribed for you, including enfuvirtide. Keep using this medicine for the full time of treatment even if you ...